Smiths Medical wins FDA clearance for 'smart' infusion pump
CADD infusion pump--
courtesy of Smiths Medical
The FDA gave 510(k) clearance to Smiths Medical's "smart" infusion pump, which includes error-prevention software for a number of therapies. The company says its CADD-Solis VIP pump improves on the patient interface and minimizes the potential for device failure.
The FDA gave the nod to the Minnesota-based Smiths on the heels of several recalls in the infusion pump industry last year, including ones from such heavy hitters as Hospira ($HSP), Baxter International ($BAX) and Medtronic ($MDT). Smiths Medical touts the particular safety of the new device, which can be used for treatments such as chemotherapy, antibiotics, pain management, immunoglobin infusion and total parenteral nutrition.
The CADD system recognizes prescription errors, dose misinterpretations and keypad programming errors, according to Smiths Medical. It lets patients know when the pump is programmed outside preconfigured limits, an innovation Smiths hopes will set the device apart from its competitors.
Smiths President Srini Seshadri said in a statement that the pump "provides enhanced safety features and convenience for health care providers who want to provide optimal care for their infusion patients in the home."
The device is already available in Canada, France, Germany, Switzerland, the Netherlands, Australia, the U.K. and the Middle East.
- here's the release
After FDA ban, Hospira creeps back into the infusion game with Q Core deal
Medtronic warns of fatal danger if pumps are used with unapproved drugs
Medtronic facing federal suit from 'exploited' patients